75 related articles for article (PubMed ID: 12390542)
21. Rapid development of vaccine protection in macaques by live-attenuated simian immunodeficiency virus.
Stahl-Hennig C; Dittmer U; Nisslein T; Petry H; Jurkiewicz E; Fuchs D; Wachter H; Mätz-Rensing K; Kuhn EM; Kaup FJ; Rud EW; Hunsmann G
J Gen Virol; 1996 Dec; 77 ( Pt 12)():2969-81. PubMed ID: 9000087
[TBL] [Abstract][Full Text] [Related]
22. Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection.
Mooij P; Nieuwenhuis IG; Knoop CJ; Doms RW; Bogers WM; Ten Haaft PJ; Niphuis H; Koornstra W; Bieler K; Köstler J; Morein B; Cafaro A; Ensoli B; Wagner R; Heeney JL
J Virol; 2004 Apr; 78(7):3333-42. PubMed ID: 15016855
[TBL] [Abstract][Full Text] [Related]
23. Differences between T cell epitopes recognized after immunization and after infection.
Vogel TU; Horton H; Fuller DH; Carter DK; Vielhuber K; O'Connor DH; Shipley T; Fuller J; Sutter G; Erfle V; Wilson N; Picker LJ; Watkins DI
J Immunol; 2002 Oct; 169(8):4511-21. PubMed ID: 12370388
[TBL] [Abstract][Full Text] [Related]
24. Simian immunodeficiency virus-specific cytotoxic T lymphocytes and protection against challenge in rhesus macaques immunized with a live attenuated simian immunodeficiency virus vaccine.
Nixon DF; Donahoe SM; Kakimoto WM; Samuel RV; Metzner KJ; Gettie A; Hanke T; Marx PA; Connor RI
Virology; 2000 Jan; 266(1):203-10. PubMed ID: 10612675
[TBL] [Abstract][Full Text] [Related]
25. Vaccine-induced, simian immunodeficiency virus-specific CD8+ T cells reduce virus replication but do not protect from simian immunodeficiency virus disease progression.
Engram JC; Dunham RM; Makedonas G; Vanderford TH; Sumpter B; Klatt NR; Ratcliffe SJ; Garg S; Paiardini M; McQuoid M; Altman JD; Staprans SI; Betts MR; Garber DA; Feinberg MB; Silvestri G
J Immunol; 2009 Jul; 183(1):706-17. PubMed ID: 19542473
[TBL] [Abstract][Full Text] [Related]
26. Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease.
McKenna PM; Koser ML; Carlson KR; Montefiori DC; Letvin NL; Papaneri AB; Pomerantz RJ; Dietzschold B; Silvera P; McGettigan JP; Schnell MJ
J Infect Dis; 2007 Apr; 195(7):980-8. PubMed ID: 17330788
[TBL] [Abstract][Full Text] [Related]
27. Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein.
Staprans SI; Barry AP; Silvestri G; Safrit JT; Kozyr N; Sumpter B; Nguyen H; McClure H; Montefiori D; Cohen JI; Feinberg MB
Proc Natl Acad Sci U S A; 2004 Aug; 101(35):13026-31. PubMed ID: 15326293
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic envelope vaccination in combination with antiretroviral therapy temporarily rescues SIV-specific CD4⁺ T-cell-dependent natural killer cell effector responses in chronically infected rhesus macaques.
Vargas-Inchaustegui DA; Xiao P; Demberg T; Pal R; Robert-Guroff M
Immunology; 2015 Jun; 145(2):288-99. PubMed ID: 25626488
[TBL] [Abstract][Full Text] [Related]
29. Fine analysis of humoral antibody response to envelope glycoprotein of SIV in infected and vaccinated macaques.
Silvera P; Flanagan B; Kent K; Rud E; Powell C; Corcoran T; Bruck C; Thiriart C; Haigwood NL; Stott EJ
AIDS Res Hum Retroviruses; 1994 Oct; 10(10):1295-304. PubMed ID: 7848685
[TBL] [Abstract][Full Text] [Related]
30. Hypervariable epitope constructs representing variability in envelope glycoprotein of SIV induce a broad humoral immune response in rabbits and rhesus macaques.
Meyer D; Anderson DE; Gardner MB; Torres JV
AIDS Res Hum Retroviruses; 1998 Jun; 14(9):751-60. PubMed ID: 9643375
[TBL] [Abstract][Full Text] [Related]
31. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.
Letvin NL; Huang Y; Chakrabarti BK; Xu L; Seaman MS; Beaudry K; Korioth-Schmitz B; Yu F; Rohne D; Martin KL; Miura A; Kong WP; Yang ZY; Gelman RS; Golubeva OG; Montefiori DC; Mascola JR; Nabel GJ
J Virol; 2004 Jul; 78(14):7490-7. PubMed ID: 15220422
[TBL] [Abstract][Full Text] [Related]
32. Involvement of multiple epitope-specific cytotoxic T-lymphocyte responses in vaccine-based control of simian immunodeficiency virus replication in rhesus macaques.
Kawada M; Igarashi H; Takeda A; Tsukamoto T; Yamamoto H; Dohki S; Takiguchi M; Matano T
J Virol; 2006 Feb; 80(4):1949-58. PubMed ID: 16439550
[TBL] [Abstract][Full Text] [Related]
33. Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen.
Zhao J; Pinczewski J; Gómez-Román VR; Venzon D; Kalyanaraman VS; Markham PD; Aldrich K; Moake M; Montefiori DC; Lou Y; Pavlakis GN; Robert-Guroff M
J Virol; 2003 Aug; 77(15):8354-65. PubMed ID: 12857905
[TBL] [Abstract][Full Text] [Related]
34. Breakthrough of SIV strain smE660 challenge in SIV strain mac239-vaccinated rhesus macaques despite potent autologous neutralizing antibody responses.
Burton SL; Kilgore KM; Smith SA; Reddy S; Hunter E; Robinson HL; Silvestri G; Amara RR; Derdeyn CA
Proc Natl Acad Sci U S A; 2015 Aug; 112(34):10780-5. PubMed ID: 26261312
[TBL] [Abstract][Full Text] [Related]
35. The simian immunodeficiency virus transmembrane protein is poorly immunogenic in inactivated virus vaccine.
Cranage MP; McBride BW; Rud EW
Vaccine; 1995 Jul; 13(10):895-900. PubMed ID: 7483761
[TBL] [Abstract][Full Text] [Related]
36. Both mucosal and systemic routes of immunization with the live, attenuated NYVAC/simian immunodeficiency virus SIV(gpe) recombinant vaccine result in gag-specific CD8(+) T-cell responses in mucosal tissues of macaques.
Stevceva L; Alvarez X; Lackner AA; Tryniszewska E; Kelsall B; Nacsa J; Tartaglia J; Strober W; Franchini G
J Virol; 2002 Nov; 76(22):11659-76. PubMed ID: 12388726
[TBL] [Abstract][Full Text] [Related]
37. Cellular immune response of rhesus monkeys infected with a partially attenuated nef deletion mutant of the simian immunodeficiency virus.
Dittmer U; Nisslein T; Bodemer W; Petry H; Sauermann U; Stahl-Hennig C; Hunsmann G
Virology; 1995 Oct; 212(2):392-7. PubMed ID: 7571408
[TBL] [Abstract][Full Text] [Related]
38. An epitope on the surface envelope glycoprotein (gp130) of simian immunodeficiency virus (SIVmac) involved in viral neutralization and T cell activation.
Torres JV; Malley A; Banapour B; Anderson DE; Axthelm MK; Gardner MB; Benjamini E
AIDS Res Hum Retroviruses; 1993 May; 9(5):423-30. PubMed ID: 7686386
[TBL] [Abstract][Full Text] [Related]
39. Impact of glycosylation on antigenicity of simian immunodeficiency virus SIV239: induction of rapid V1/V2-specific non-neutralizing antibody and delayed neutralizing antibody following infection with an attenuated deglycosylated mutant.
Sugimoto C; Nakayama EE; Shioda T; Villinger F; Ansari AA; Yamamoto N; Suzuki Y; Nagai Y; Mori K
J Gen Virol; 2008 Feb; 89(Pt 2):554-566. PubMed ID: 18198387
[TBL] [Abstract][Full Text] [Related]
40. High-Resolution Sequencing of Viral Populations during Early Simian Immunodeficiency Virus Infection Reveals Evolutionary Strategies for Rapid Escape from Emerging Env-Specific Antibody Responses.
Ita S; Hill AK; Lam EC; Dufort FJ; Yang X; Newman R; Leviyang S; Fofana IB; Johnson WE
J Virol; 2018 Apr; 92(7):. PubMed ID: 29343575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
